Global Antiviral Immunoglobulin Market Growth 2026-2032
The global Antiviral Immunoglobulin market size is predicted to grow from US$ 11011 million in 2025 to US$ 17428 million in 2032; it is expected to grow at a CAGR of 6.8% from 2026 to 2032.
Antiviral immunoglobulin refers to a class of biological medicinal products containing specific antibodies used for the prevention (prophylaxis) or treatment of viral diseases, operating on the principle of passive immunization. In 2025,global antiviral immunoglobulin production reached approximately 1,731K Kg, with an average global market price of around USD 6,500 per Kg. A factory gross profit of USD 1,950 per Kg with 30% gross margin. A single line full machine capacity production is around 25K Kg per line per year.The upstream segment is highly dependent on the global human plasma supply chain. Downstream demand is concentrated in hospitals,emergency care and research and specialty clinics. A hepatitis B-positive liver transplant recipient receives HBIG therapy following transplantation to reduce the risk of viral recurrence and graft failure. China isleading due to aggressive expansion of plasma-derived biologics manufacturing, increasing healthcare expenditure, and growing domestic demand for immunotherapy products. while US following due to advanced transplant medicine, high immunoglobulin utilization rates, strong reimbursement systems, and continuous expansion of plasma donation infrastructure.
United States market for Antiviral Immunoglobulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Antiviral Immunoglobulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Antiviral Immunoglobulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Antiviral Immunoglobulin players cover ADMA Biologics (US), AstraZeneca (UK/Sweden), Bharat Serums & Vaccines (India), Biotest (Germany), Boya Bio (China), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Antiviral Immunoglobulin Industry Forecast? looks at past sales and reviews total world Antiviral Immunoglobulin sales in 2025, providing a comprehensive analysis by region and market sector of projected Antiviral Immunoglobulin sales for 2026 through 2032. With Antiviral Immunoglobulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antiviral Immunoglobulin industry.
This Insight Report provides a comprehensive analysis of the global Antiviral Immunoglobulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antiviral Immunoglobulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Antiviral Immunoglobulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antiviral Immunoglobulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antiviral Immunoglobulin.
This report presents a comprehensive overview, market shares, and growth opportunities of Antiviral Immunoglobulin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Antiviral Immunoglobulin market?
What factors are driving Antiviral Immunoglobulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antiviral Immunoglobulin market opportunities vary by end market size?
How does Antiviral Immunoglobulin break out by Type, by Application?
Antiviral immunoglobulin refers to a class of biological medicinal products containing specific antibodies used for the prevention (prophylaxis) or treatment of viral diseases, operating on the principle of passive immunization. In 2025,global antiviral immunoglobulin production reached approximately 1,731K Kg, with an average global market price of around USD 6,500 per Kg. A factory gross profit of USD 1,950 per Kg with 30% gross margin. A single line full machine capacity production is around 25K Kg per line per year.The upstream segment is highly dependent on the global human plasma supply chain. Downstream demand is concentrated in hospitals,emergency care and research and specialty clinics. A hepatitis B-positive liver transplant recipient receives HBIG therapy following transplantation to reduce the risk of viral recurrence and graft failure. China isleading due to aggressive expansion of plasma-derived biologics manufacturing, increasing healthcare expenditure, and growing domestic demand for immunotherapy products. while US following due to advanced transplant medicine, high immunoglobulin utilization rates, strong reimbursement systems, and continuous expansion of plasma donation infrastructure.
United States market for Antiviral Immunoglobulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Antiviral Immunoglobulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Antiviral Immunoglobulin is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Antiviral Immunoglobulin players cover ADMA Biologics (US), AstraZeneca (UK/Sweden), Bharat Serums & Vaccines (India), Biotest (Germany), Boya Bio (China), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Antiviral Immunoglobulin Industry Forecast? looks at past sales and reviews total world Antiviral Immunoglobulin sales in 2025, providing a comprehensive analysis by region and market sector of projected Antiviral Immunoglobulin sales for 2026 through 2032. With Antiviral Immunoglobulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antiviral Immunoglobulin industry.
This Insight Report provides a comprehensive analysis of the global Antiviral Immunoglobulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antiviral Immunoglobulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Antiviral Immunoglobulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antiviral Immunoglobulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antiviral Immunoglobulin.
This report presents a comprehensive overview, market shares, and growth opportunities of Antiviral Immunoglobulin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Human Plasma Derived Polyclonal
- Hyperimmune Specific Globulin
- Recombinant Monoclonal Antibody (mAb)
- Animal Derived (Equine/Ovine)
- Others
- Standard Fractionated Grade (90%?95%)
- Clinical High Purity Grade (96%?98%)
- Ultra Purified Specialty Grade(99%)
- Transplantation
- Infectious Disease Prophylaxis
- Immunodeficiency
- Neurology (Autoimmune)
- Others
- Hospitals
- Specialty Clinics
- Home Care
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- ADMA Biologics (US)
- AstraZeneca (UK/Sweden)
- Bharat Serums & Vaccines (India)
- Biotest (Germany)
- Boya Bio (China)
- China Biologic Products (CNBG) (China)
- CSL Behring (US/Germany)
- Emergent BioSolutions (US)
- GC Pharma (S. Korea)
- Grifols (Spain)
- Hualan Biological (China)
- Intas Pharmaceuticals (India)
- Kamada (Israel)
- Kedrion (Italy)
- LFB Group (France)
- Octapharma (Switzerland)
- Regeneron (US)
- Roche (Switzerland)
- Sanofi (France)
- Shanghai RAAS (China)
- Shuanglin Bio (China)
- SK Plasma (S. Korea)
- Takeda Pharmaceutical (Japan)
- Tiantan Bio (China)
- Weiguang Biological (China)
- Yuanda Shuyang (China)
What is the 10-year outlook for the global Antiviral Immunoglobulin market?
What factors are driving Antiviral Immunoglobulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antiviral Immunoglobulin market opportunities vary by end market size?
How does Antiviral Immunoglobulin break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antiviral Immunoglobulin Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Antiviral Immunoglobulin by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Antiviral Immunoglobulin by Country/Region, 2021, 2025 & 2032
2.2 Antiviral Immunoglobulin Segment by Type
2.2.1 Human Plasma Derived Polyclonal
2.2.2 Hyperimmune Specific Globulin
2.2.3 Recombinant Monoclonal Antibody (mAb)
2.2.4 Animal Derived (Equine/Ovine)
2.2.5 Others
2.2.6 Antiviral Immunoglobulin Sales by Type
2.2.6.1 Global Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
2.2.6.2 Global Antiviral Immunoglobulin Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Antiviral Immunoglobulin Sale Price by Type (2021-2026)
2.3 Antiviral Immunoglobulin Segment by IgG Purity
2.3.1 Standard Fractionated Grade (90%?95%)
2.3.2 Clinical High Purity Grade (96%?98%)
2.3.3 Ultra Purified Specialty Grade(99%)
2.3.4 Antiviral Immunoglobulin Sales by IgG Purity
2.3.4.1 Global Antiviral Immunoglobulin Sales Market Share by IgG Purity (2021-2026)
2.3.4.2 Global Antiviral Immunoglobulin Revenue and Market Share by IgG Purity (2021-2026)
2.3.4.3 Global Antiviral Immunoglobulin Sale Price by IgG Purity (2021-2026)
2.4 Antiviral Immunoglobulin Segment by Therapeutic Area
2.4.1 Transplantation
2.4.2 Infectious Disease Prophylaxis
2.4.3 Immunodeficiency
2.4.4 Neurology (Autoimmune)
2.4.5 Others
2.4.6 Antiviral Immunoglobulin Sales by Therapeutic Area
2.4.6.1 Global Antiviral Immunoglobulin Sales Market Share by Therapeutic Area (2021-2026)
2.4.6.2 Global Antiviral Immunoglobulin Revenue and Market Share by Therapeutic Area (2021-2026)
2.4.6.3 Global Antiviral Immunoglobulin Sale Price by Therapeutic Area (2021-2026)
2.5 Antiviral Immunoglobulin Segment by Application
2.5.1 Hospitals
2.5.2 Specialty Clinics
2.5.3 Home Care
2.5.4 Others
2.5.5 Antiviral Immunoglobulin Sales by Application
2.5.5.1 Global Antiviral Immunoglobulin Sale Market Share by Application (2021-2026)
2.5.5.2 Global Antiviral Immunoglobulin Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Antiviral Immunoglobulin Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Antiviral Immunoglobulin Breakdown Data by Company
3.1.1 Global Antiviral Immunoglobulin Annual Sales by Company (2021-2026)
3.1.2 Global Antiviral Immunoglobulin Sales Market Share by Company (2021-2026)
3.2 Global Antiviral Immunoglobulin Annual Revenue by Company (2021-2026)
3.2.1 Global Antiviral Immunoglobulin Revenue by Company (2021-2026)
3.2.2 Global Antiviral Immunoglobulin Revenue Market Share by Company (2021-2026)
3.3 Global Antiviral Immunoglobulin Sale Price by Company
3.4 Key Manufacturers Antiviral Immunoglobulin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antiviral Immunoglobulin Product Location Distribution
3.4.2 Players Antiviral Immunoglobulin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTIVIRAL IMMUNOGLOBULIN BY GEOGRAPHIC REGION
4.1 World Historic Antiviral Immunoglobulin Market Size by Geographic Region (2021-2026)
4.1.1 Global Antiviral Immunoglobulin Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Antiviral Immunoglobulin Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Antiviral Immunoglobulin Market Size by Country/Region (2021-2026)
4.2.1 Global Antiviral Immunoglobulin Annual Sales by Country/Region (2021-2026)
4.2.2 Global Antiviral Immunoglobulin Annual Revenue by Country/Region (2021-2026)
4.3 Americas Antiviral Immunoglobulin Sales Growth
4.4 APAC Antiviral Immunoglobulin Sales Growth
4.5 Europe Antiviral Immunoglobulin Sales Growth
4.6 Middle East & Africa Antiviral Immunoglobulin Sales Growth
5 AMERICAS
5.1 Americas Antiviral Immunoglobulin Sales by Country
5.1.1 Americas Antiviral Immunoglobulin Sales by Country (2021-2026)
5.1.2 Americas Antiviral Immunoglobulin Revenue by Country (2021-2026)
5.2 Americas Antiviral Immunoglobulin Sales by Type (2021-2026)
5.3 Americas Antiviral Immunoglobulin Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antiviral Immunoglobulin Sales by Region
6.1.1 APAC Antiviral Immunoglobulin Sales by Region (2021-2026)
6.1.2 APAC Antiviral Immunoglobulin Revenue by Region (2021-2026)
6.2 APAC Antiviral Immunoglobulin Sales by Type (2021-2026)
6.3 APAC Antiviral Immunoglobulin Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antiviral Immunoglobulin by Country
7.1.1 Europe Antiviral Immunoglobulin Sales by Country (2021-2026)
7.1.2 Europe Antiviral Immunoglobulin Revenue by Country (2021-2026)
7.2 Europe Antiviral Immunoglobulin Sales by Type (2021-2026)
7.3 Europe Antiviral Immunoglobulin Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antiviral Immunoglobulin by Country
8.1.1 Middle East & Africa Antiviral Immunoglobulin Sales by Country (2021-2026)
8.1.2 Middle East & Africa Antiviral Immunoglobulin Revenue by Country (2021-2026)
8.2 Middle East & Africa Antiviral Immunoglobulin Sales by Type (2021-2026)
8.3 Middle East & Africa Antiviral Immunoglobulin Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antiviral Immunoglobulin
10.3 Manufacturing Process Analysis of Antiviral Immunoglobulin
10.4 Industry Chain Structure of Antiviral Immunoglobulin
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antiviral Immunoglobulin Distributors
11.3 Antiviral Immunoglobulin Customer
12 WORLD FORECAST REVIEW FOR ANTIVIRAL IMMUNOGLOBULIN BY GEOGRAPHIC REGION
12.1 Global Antiviral Immunoglobulin Market Size Forecast by Region
12.1.1 Global Antiviral Immunoglobulin Forecast by Region (2027-2032)
12.1.2 Global Antiviral Immunoglobulin Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Antiviral Immunoglobulin Forecast by Type (2027-2032)
12.7 Global Antiviral Immunoglobulin Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ADMA Biologics (US)
13.1.1 ADMA Biologics (US) Company Information
13.1.2 ADMA Biologics (US) Antiviral Immunoglobulin Product Portfolios and Specifications
13.1.3 ADMA Biologics (US) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ADMA Biologics (US) Main Business Overview
13.1.5 ADMA Biologics (US) Latest Developments
13.2 AstraZeneca (UK/Sweden)
13.2.1 AstraZeneca (UK/Sweden) Company Information
13.2.2 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Product Portfolios and Specifications
13.2.3 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 AstraZeneca (UK/Sweden) Main Business Overview
13.2.5 AstraZeneca (UK/Sweden) Latest Developments
13.3 Bharat Serums & Vaccines (India)
13.3.1 Bharat Serums & Vaccines (India) Company Information
13.3.2 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Product Portfolios and Specifications
13.3.3 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bharat Serums & Vaccines (India) Main Business Overview
13.3.5 Bharat Serums & Vaccines (India) Latest Developments
13.4 Biotest (Germany)
13.4.1 Biotest (Germany) Company Information
13.4.2 Biotest (Germany) Antiviral Immunoglobulin Product Portfolios and Specifications
13.4.3 Biotest (Germany) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Biotest (Germany) Main Business Overview
13.4.5 Biotest (Germany) Latest Developments
13.5 Boya Bio (China)
13.5.1 Boya Bio (China) Company Information
13.5.2 Boya Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.5.3 Boya Bio (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Boya Bio (China) Main Business Overview
13.5.5 Boya Bio (China) Latest Developments
13.6 China Biologic Products (CNBG) (China)
13.6.1 China Biologic Products (CNBG) (China) Company Information
13.6.2 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.6.3 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 China Biologic Products (CNBG) (China) Main Business Overview
13.6.5 China Biologic Products (CNBG) (China) Latest Developments
13.7 CSL Behring (US/Germany)
13.7.1 CSL Behring (US/Germany) Company Information
13.7.2 CSL Behring (US/Germany) Antiviral Immunoglobulin Product Portfolios and Specifications
13.7.3 CSL Behring (US/Germany) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 CSL Behring (US/Germany) Main Business Overview
13.7.5 CSL Behring (US/Germany) Latest Developments
13.8 Emergent BioSolutions (US)
13.8.1 Emergent BioSolutions (US) Company Information
13.8.2 Emergent BioSolutions (US) Antiviral Immunoglobulin Product Portfolios and Specifications
13.8.3 Emergent BioSolutions (US) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Emergent BioSolutions (US) Main Business Overview
13.8.5 Emergent BioSolutions (US) Latest Developments
13.9 GC Pharma (S. Korea)
13.9.1 GC Pharma (S. Korea) Company Information
13.9.2 GC Pharma (S. Korea) Antiviral Immunoglobulin Product Portfolios and Specifications
13.9.3 GC Pharma (S. Korea) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 GC Pharma (S. Korea) Main Business Overview
13.9.5 GC Pharma (S. Korea) Latest Developments
13.10 Grifols (Spain)
13.10.1 Grifols (Spain) Company Information
13.10.2 Grifols (Spain) Antiviral Immunoglobulin Product Portfolios and Specifications
13.10.3 Grifols (Spain) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Grifols (Spain) Main Business Overview
13.10.5 Grifols (Spain) Latest Developments
13.11 Hualan Biological (China)
13.11.1 Hualan Biological (China) Company Information
13.11.2 Hualan Biological (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.11.3 Hualan Biological (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Hualan Biological (China) Main Business Overview
13.11.5 Hualan Biological (China) Latest Developments
13.12 Intas Pharmaceuticals (India)
13.12.1 Intas Pharmaceuticals (India) Company Information
13.12.2 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Product Portfolios and Specifications
13.12.3 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Intas Pharmaceuticals (India) Main Business Overview
13.12.5 Intas Pharmaceuticals (India) Latest Developments
13.13 Kamada (Israel)
13.13.1 Kamada (Israel) Company Information
13.13.2 Kamada (Israel) Antiviral Immunoglobulin Product Portfolios and Specifications
13.13.3 Kamada (Israel) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Kamada (Israel) Main Business Overview
13.13.5 Kamada (Israel) Latest Developments
13.14 Kedrion (Italy)
13.14.1 Kedrion (Italy) Company Information
13.14.2 Kedrion (Italy) Antiviral Immunoglobulin Product Portfolios and Specifications
13.14.3 Kedrion (Italy) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Kedrion (Italy) Main Business Overview
13.14.5 Kedrion (Italy) Latest Developments
13.15 LFB Group (France)
13.15.1 LFB Group (France) Company Information
13.15.2 LFB Group (France) Antiviral Immunoglobulin Product Portfolios and Specifications
13.15.3 LFB Group (France) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 LFB Group (France) Main Business Overview
13.15.5 LFB Group (France) Latest Developments
13.16 Octapharma (Switzerland)
13.16.1 Octapharma (Switzerland) Company Information
13.16.2 Octapharma (Switzerland) Antiviral Immunoglobulin Product Portfolios and Specifications
13.16.3 Octapharma (Switzerland) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Octapharma (Switzerland) Main Business Overview
13.16.5 Octapharma (Switzerland) Latest Developments
13.17 Regeneron (US)
13.17.1 Regeneron (US) Company Information
13.17.2 Regeneron (US) Antiviral Immunoglobulin Product Portfolios and Specifications
13.17.3 Regeneron (US) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Regeneron (US) Main Business Overview
13.17.5 Regeneron (US) Latest Developments
13.18 Roche (Switzerland)
13.18.1 Roche (Switzerland) Company Information
13.18.2 Roche (Switzerland) Antiviral Immunoglobulin Product Portfolios and Specifications
13.18.3 Roche (Switzerland) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Roche (Switzerland) Main Business Overview
13.18.5 Roche (Switzerland) Latest Developments
13.19 Sanofi (France)
13.19.1 Sanofi (France) Company Information
13.19.2 Sanofi (France) Antiviral Immunoglobulin Product Portfolios and Specifications
13.19.3 Sanofi (France) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Sanofi (France) Main Business Overview
13.19.5 Sanofi (France) Latest Developments
13.20 Shanghai RAAS (China)
13.20.1 Shanghai RAAS (China) Company Information
13.20.2 Shanghai RAAS (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.20.3 Shanghai RAAS (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Shanghai RAAS (China) Main Business Overview
13.20.5 Shanghai RAAS (China) Latest Developments
13.21 Shuanglin Bio (China)
13.21.1 Shuanglin Bio (China) Company Information
13.21.2 Shuanglin Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.21.3 Shuanglin Bio (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Shuanglin Bio (China) Main Business Overview
13.21.5 Shuanglin Bio (China) Latest Developments
13.22 SK Plasma (S. Korea)
13.22.1 SK Plasma (S. Korea) Company Information
13.22.2 SK Plasma (S. Korea) Antiviral Immunoglobulin Product Portfolios and Specifications
13.22.3 SK Plasma (S. Korea) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 SK Plasma (S. Korea) Main Business Overview
13.22.5 SK Plasma (S. Korea) Latest Developments
13.23 Takeda Pharmaceutical (Japan)
13.23.1 Takeda Pharmaceutical (Japan) Company Information
13.23.2 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Product Portfolios and Specifications
13.23.3 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Takeda Pharmaceutical (Japan) Main Business Overview
13.23.5 Takeda Pharmaceutical (Japan) Latest Developments
13.24 Tiantan Bio (China)
13.24.1 Tiantan Bio (China) Company Information
13.24.2 Tiantan Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.24.3 Tiantan Bio (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Tiantan Bio (China) Main Business Overview
13.24.5 Tiantan Bio (China) Latest Developments
13.25 Weiguang Biological (China)
13.25.1 Weiguang Biological (China) Company Information
13.25.2 Weiguang Biological (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.25.3 Weiguang Biological (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Weiguang Biological (China) Main Business Overview
13.25.5 Weiguang Biological (China) Latest Developments
13.26 Yuanda Shuyang (China)
13.26.1 Yuanda Shuyang (China) Company Information
13.26.2 Yuanda Shuyang (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.26.3 Yuanda Shuyang (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Yuanda Shuyang (China) Main Business Overview
13.26.5 Yuanda Shuyang (China) Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antiviral Immunoglobulin Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Antiviral Immunoglobulin by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Antiviral Immunoglobulin by Country/Region, 2021, 2025 & 2032
2.2 Antiviral Immunoglobulin Segment by Type
2.2.1 Human Plasma Derived Polyclonal
2.2.2 Hyperimmune Specific Globulin
2.2.3 Recombinant Monoclonal Antibody (mAb)
2.2.4 Animal Derived (Equine/Ovine)
2.2.5 Others
2.2.6 Antiviral Immunoglobulin Sales by Type
2.2.6.1 Global Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
2.2.6.2 Global Antiviral Immunoglobulin Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Antiviral Immunoglobulin Sale Price by Type (2021-2026)
2.3 Antiviral Immunoglobulin Segment by IgG Purity
2.3.1 Standard Fractionated Grade (90%?95%)
2.3.2 Clinical High Purity Grade (96%?98%)
2.3.3 Ultra Purified Specialty Grade(99%)
2.3.4 Antiviral Immunoglobulin Sales by IgG Purity
2.3.4.1 Global Antiviral Immunoglobulin Sales Market Share by IgG Purity (2021-2026)
2.3.4.2 Global Antiviral Immunoglobulin Revenue and Market Share by IgG Purity (2021-2026)
2.3.4.3 Global Antiviral Immunoglobulin Sale Price by IgG Purity (2021-2026)
2.4 Antiviral Immunoglobulin Segment by Therapeutic Area
2.4.1 Transplantation
2.4.2 Infectious Disease Prophylaxis
2.4.3 Immunodeficiency
2.4.4 Neurology (Autoimmune)
2.4.5 Others
2.4.6 Antiviral Immunoglobulin Sales by Therapeutic Area
2.4.6.1 Global Antiviral Immunoglobulin Sales Market Share by Therapeutic Area (2021-2026)
2.4.6.2 Global Antiviral Immunoglobulin Revenue and Market Share by Therapeutic Area (2021-2026)
2.4.6.3 Global Antiviral Immunoglobulin Sale Price by Therapeutic Area (2021-2026)
2.5 Antiviral Immunoglobulin Segment by Application
2.5.1 Hospitals
2.5.2 Specialty Clinics
2.5.3 Home Care
2.5.4 Others
2.5.5 Antiviral Immunoglobulin Sales by Application
2.5.5.1 Global Antiviral Immunoglobulin Sale Market Share by Application (2021-2026)
2.5.5.2 Global Antiviral Immunoglobulin Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Antiviral Immunoglobulin Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Antiviral Immunoglobulin Breakdown Data by Company
3.1.1 Global Antiviral Immunoglobulin Annual Sales by Company (2021-2026)
3.1.2 Global Antiviral Immunoglobulin Sales Market Share by Company (2021-2026)
3.2 Global Antiviral Immunoglobulin Annual Revenue by Company (2021-2026)
3.2.1 Global Antiviral Immunoglobulin Revenue by Company (2021-2026)
3.2.2 Global Antiviral Immunoglobulin Revenue Market Share by Company (2021-2026)
3.3 Global Antiviral Immunoglobulin Sale Price by Company
3.4 Key Manufacturers Antiviral Immunoglobulin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antiviral Immunoglobulin Product Location Distribution
3.4.2 Players Antiviral Immunoglobulin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTIVIRAL IMMUNOGLOBULIN BY GEOGRAPHIC REGION
4.1 World Historic Antiviral Immunoglobulin Market Size by Geographic Region (2021-2026)
4.1.1 Global Antiviral Immunoglobulin Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Antiviral Immunoglobulin Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Antiviral Immunoglobulin Market Size by Country/Region (2021-2026)
4.2.1 Global Antiviral Immunoglobulin Annual Sales by Country/Region (2021-2026)
4.2.2 Global Antiviral Immunoglobulin Annual Revenue by Country/Region (2021-2026)
4.3 Americas Antiviral Immunoglobulin Sales Growth
4.4 APAC Antiviral Immunoglobulin Sales Growth
4.5 Europe Antiviral Immunoglobulin Sales Growth
4.6 Middle East & Africa Antiviral Immunoglobulin Sales Growth
5 AMERICAS
5.1 Americas Antiviral Immunoglobulin Sales by Country
5.1.1 Americas Antiviral Immunoglobulin Sales by Country (2021-2026)
5.1.2 Americas Antiviral Immunoglobulin Revenue by Country (2021-2026)
5.2 Americas Antiviral Immunoglobulin Sales by Type (2021-2026)
5.3 Americas Antiviral Immunoglobulin Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antiviral Immunoglobulin Sales by Region
6.1.1 APAC Antiviral Immunoglobulin Sales by Region (2021-2026)
6.1.2 APAC Antiviral Immunoglobulin Revenue by Region (2021-2026)
6.2 APAC Antiviral Immunoglobulin Sales by Type (2021-2026)
6.3 APAC Antiviral Immunoglobulin Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antiviral Immunoglobulin by Country
7.1.1 Europe Antiviral Immunoglobulin Sales by Country (2021-2026)
7.1.2 Europe Antiviral Immunoglobulin Revenue by Country (2021-2026)
7.2 Europe Antiviral Immunoglobulin Sales by Type (2021-2026)
7.3 Europe Antiviral Immunoglobulin Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antiviral Immunoglobulin by Country
8.1.1 Middle East & Africa Antiviral Immunoglobulin Sales by Country (2021-2026)
8.1.2 Middle East & Africa Antiviral Immunoglobulin Revenue by Country (2021-2026)
8.2 Middle East & Africa Antiviral Immunoglobulin Sales by Type (2021-2026)
8.3 Middle East & Africa Antiviral Immunoglobulin Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antiviral Immunoglobulin
10.3 Manufacturing Process Analysis of Antiviral Immunoglobulin
10.4 Industry Chain Structure of Antiviral Immunoglobulin
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antiviral Immunoglobulin Distributors
11.3 Antiviral Immunoglobulin Customer
12 WORLD FORECAST REVIEW FOR ANTIVIRAL IMMUNOGLOBULIN BY GEOGRAPHIC REGION
12.1 Global Antiviral Immunoglobulin Market Size Forecast by Region
12.1.1 Global Antiviral Immunoglobulin Forecast by Region (2027-2032)
12.1.2 Global Antiviral Immunoglobulin Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Antiviral Immunoglobulin Forecast by Type (2027-2032)
12.7 Global Antiviral Immunoglobulin Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ADMA Biologics (US)
13.1.1 ADMA Biologics (US) Company Information
13.1.2 ADMA Biologics (US) Antiviral Immunoglobulin Product Portfolios and Specifications
13.1.3 ADMA Biologics (US) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ADMA Biologics (US) Main Business Overview
13.1.5 ADMA Biologics (US) Latest Developments
13.2 AstraZeneca (UK/Sweden)
13.2.1 AstraZeneca (UK/Sweden) Company Information
13.2.2 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Product Portfolios and Specifications
13.2.3 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 AstraZeneca (UK/Sweden) Main Business Overview
13.2.5 AstraZeneca (UK/Sweden) Latest Developments
13.3 Bharat Serums & Vaccines (India)
13.3.1 Bharat Serums & Vaccines (India) Company Information
13.3.2 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Product Portfolios and Specifications
13.3.3 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bharat Serums & Vaccines (India) Main Business Overview
13.3.5 Bharat Serums & Vaccines (India) Latest Developments
13.4 Biotest (Germany)
13.4.1 Biotest (Germany) Company Information
13.4.2 Biotest (Germany) Antiviral Immunoglobulin Product Portfolios and Specifications
13.4.3 Biotest (Germany) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Biotest (Germany) Main Business Overview
13.4.5 Biotest (Germany) Latest Developments
13.5 Boya Bio (China)
13.5.1 Boya Bio (China) Company Information
13.5.2 Boya Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.5.3 Boya Bio (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Boya Bio (China) Main Business Overview
13.5.5 Boya Bio (China) Latest Developments
13.6 China Biologic Products (CNBG) (China)
13.6.1 China Biologic Products (CNBG) (China) Company Information
13.6.2 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.6.3 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 China Biologic Products (CNBG) (China) Main Business Overview
13.6.5 China Biologic Products (CNBG) (China) Latest Developments
13.7 CSL Behring (US/Germany)
13.7.1 CSL Behring (US/Germany) Company Information
13.7.2 CSL Behring (US/Germany) Antiviral Immunoglobulin Product Portfolios and Specifications
13.7.3 CSL Behring (US/Germany) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 CSL Behring (US/Germany) Main Business Overview
13.7.5 CSL Behring (US/Germany) Latest Developments
13.8 Emergent BioSolutions (US)
13.8.1 Emergent BioSolutions (US) Company Information
13.8.2 Emergent BioSolutions (US) Antiviral Immunoglobulin Product Portfolios and Specifications
13.8.3 Emergent BioSolutions (US) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Emergent BioSolutions (US) Main Business Overview
13.8.5 Emergent BioSolutions (US) Latest Developments
13.9 GC Pharma (S. Korea)
13.9.1 GC Pharma (S. Korea) Company Information
13.9.2 GC Pharma (S. Korea) Antiviral Immunoglobulin Product Portfolios and Specifications
13.9.3 GC Pharma (S. Korea) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 GC Pharma (S. Korea) Main Business Overview
13.9.5 GC Pharma (S. Korea) Latest Developments
13.10 Grifols (Spain)
13.10.1 Grifols (Spain) Company Information
13.10.2 Grifols (Spain) Antiviral Immunoglobulin Product Portfolios and Specifications
13.10.3 Grifols (Spain) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Grifols (Spain) Main Business Overview
13.10.5 Grifols (Spain) Latest Developments
13.11 Hualan Biological (China)
13.11.1 Hualan Biological (China) Company Information
13.11.2 Hualan Biological (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.11.3 Hualan Biological (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Hualan Biological (China) Main Business Overview
13.11.5 Hualan Biological (China) Latest Developments
13.12 Intas Pharmaceuticals (India)
13.12.1 Intas Pharmaceuticals (India) Company Information
13.12.2 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Product Portfolios and Specifications
13.12.3 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Intas Pharmaceuticals (India) Main Business Overview
13.12.5 Intas Pharmaceuticals (India) Latest Developments
13.13 Kamada (Israel)
13.13.1 Kamada (Israel) Company Information
13.13.2 Kamada (Israel) Antiviral Immunoglobulin Product Portfolios and Specifications
13.13.3 Kamada (Israel) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Kamada (Israel) Main Business Overview
13.13.5 Kamada (Israel) Latest Developments
13.14 Kedrion (Italy)
13.14.1 Kedrion (Italy) Company Information
13.14.2 Kedrion (Italy) Antiviral Immunoglobulin Product Portfolios and Specifications
13.14.3 Kedrion (Italy) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Kedrion (Italy) Main Business Overview
13.14.5 Kedrion (Italy) Latest Developments
13.15 LFB Group (France)
13.15.1 LFB Group (France) Company Information
13.15.2 LFB Group (France) Antiviral Immunoglobulin Product Portfolios and Specifications
13.15.3 LFB Group (France) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 LFB Group (France) Main Business Overview
13.15.5 LFB Group (France) Latest Developments
13.16 Octapharma (Switzerland)
13.16.1 Octapharma (Switzerland) Company Information
13.16.2 Octapharma (Switzerland) Antiviral Immunoglobulin Product Portfolios and Specifications
13.16.3 Octapharma (Switzerland) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Octapharma (Switzerland) Main Business Overview
13.16.5 Octapharma (Switzerland) Latest Developments
13.17 Regeneron (US)
13.17.1 Regeneron (US) Company Information
13.17.2 Regeneron (US) Antiviral Immunoglobulin Product Portfolios and Specifications
13.17.3 Regeneron (US) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Regeneron (US) Main Business Overview
13.17.5 Regeneron (US) Latest Developments
13.18 Roche (Switzerland)
13.18.1 Roche (Switzerland) Company Information
13.18.2 Roche (Switzerland) Antiviral Immunoglobulin Product Portfolios and Specifications
13.18.3 Roche (Switzerland) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Roche (Switzerland) Main Business Overview
13.18.5 Roche (Switzerland) Latest Developments
13.19 Sanofi (France)
13.19.1 Sanofi (France) Company Information
13.19.2 Sanofi (France) Antiviral Immunoglobulin Product Portfolios and Specifications
13.19.3 Sanofi (France) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Sanofi (France) Main Business Overview
13.19.5 Sanofi (France) Latest Developments
13.20 Shanghai RAAS (China)
13.20.1 Shanghai RAAS (China) Company Information
13.20.2 Shanghai RAAS (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.20.3 Shanghai RAAS (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Shanghai RAAS (China) Main Business Overview
13.20.5 Shanghai RAAS (China) Latest Developments
13.21 Shuanglin Bio (China)
13.21.1 Shuanglin Bio (China) Company Information
13.21.2 Shuanglin Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.21.3 Shuanglin Bio (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Shuanglin Bio (China) Main Business Overview
13.21.5 Shuanglin Bio (China) Latest Developments
13.22 SK Plasma (S. Korea)
13.22.1 SK Plasma (S. Korea) Company Information
13.22.2 SK Plasma (S. Korea) Antiviral Immunoglobulin Product Portfolios and Specifications
13.22.3 SK Plasma (S. Korea) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 SK Plasma (S. Korea) Main Business Overview
13.22.5 SK Plasma (S. Korea) Latest Developments
13.23 Takeda Pharmaceutical (Japan)
13.23.1 Takeda Pharmaceutical (Japan) Company Information
13.23.2 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Product Portfolios and Specifications
13.23.3 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Takeda Pharmaceutical (Japan) Main Business Overview
13.23.5 Takeda Pharmaceutical (Japan) Latest Developments
13.24 Tiantan Bio (China)
13.24.1 Tiantan Bio (China) Company Information
13.24.2 Tiantan Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.24.3 Tiantan Bio (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Tiantan Bio (China) Main Business Overview
13.24.5 Tiantan Bio (China) Latest Developments
13.25 Weiguang Biological (China)
13.25.1 Weiguang Biological (China) Company Information
13.25.2 Weiguang Biological (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.25.3 Weiguang Biological (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Weiguang Biological (China) Main Business Overview
13.25.5 Weiguang Biological (China) Latest Developments
13.26 Yuanda Shuyang (China)
13.26.1 Yuanda Shuyang (China) Company Information
13.26.2 Yuanda Shuyang (China) Antiviral Immunoglobulin Product Portfolios and Specifications
13.26.3 Yuanda Shuyang (China) Antiviral Immunoglobulin Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Yuanda Shuyang (China) Main Business Overview
13.26.5 Yuanda Shuyang (China) Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Antiviral Immunoglobulin Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Antiviral Immunoglobulin Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Human Plasma Derived Polyclonal
Table 4. Major Players of Hyperimmune Specific Globulin
Table 5. Major Players of Recombinant Monoclonal Antibody (mAb)
Table 6. Major Players of Animal Derived (Equine/Ovine)
Table 7. Major Players of Others
Table 8. Global Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 9. Global Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Table 10. Global Antiviral Immunoglobulin Revenue by Type (2021-2026) & ($ million)
Table 11. Global Antiviral Immunoglobulin Revenue Market Share by Type (2021-2026)
Table 12. Global Antiviral Immunoglobulin Sale Price by Type (2021-2026) & (US$/kg)
Table 13. Major Players of Standard Fractionated Grade (90%?95%)
Table 14. Major Players of Clinical High Purity Grade (96%?98%)
Table 15. Major Players of Ultra Purified Specialty Grade(99%)
Table 16. Global Antiviral Immunoglobulin Sales by IgG Purity (2021-2026) & (kg)
Table 17. Global Antiviral Immunoglobulin Sales Market Share by IgG Purity (2021-2026)
Table 18. Global Antiviral Immunoglobulin Revenue by IgG Purity (2021-2026) & ($ million)
Table 19. Global Antiviral Immunoglobulin Revenue Market Share by IgG Purity (2021-2026)
Table 20. Global Antiviral Immunoglobulin Sale Price by IgG Purity (2021-2026) & (US$/kg)
Table 21. Major Players of Transplantation
Table 22. Major Players of Infectious Disease Prophylaxis
Table 23. Major Players of Immunodeficiency
Table 24. Major Players of Neurology (Autoimmune)
Table 25. Major Players of Others
Table 26. Global Antiviral Immunoglobulin Sales by Therapeutic Area (2021-2026) & (kg)
Table 27. Global Antiviral Immunoglobulin Sales Market Share by Therapeutic Area (2021-2026)
Table 28. Global Antiviral Immunoglobulin Revenue by Therapeutic Area (2021-2026) & ($ million)
Table 29. Global Antiviral Immunoglobulin Revenue Market Share by Therapeutic Area (2021-2026)
Table 30. Global Antiviral Immunoglobulin Sale Price by Therapeutic Area (2021-2026) & (US$/kg)
Table 31. Global Antiviral Immunoglobulin Sale by Application (2021-2026) & (kg)
Table 32. Global Antiviral Immunoglobulin Sale Market Share by Application (2021-2026)
Table 33. Global Antiviral Immunoglobulin Revenue by Application (2021-2026) & ($ million)
Table 34. Global Antiviral Immunoglobulin Revenue Market Share by Application (2021-2026)
Table 35. Global Antiviral Immunoglobulin Sale Price by Application (2021-2026) & (US$/kg)
Table 36. Global Antiviral Immunoglobulin Sales by Company (2021-2026) & (kg)
Table 37. Global Antiviral Immunoglobulin Sales Market Share by Company (2021-2026)
Table 38. Global Antiviral Immunoglobulin Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Antiviral Immunoglobulin Revenue Market Share by Company (2021-2026)
Table 40. Global Antiviral Immunoglobulin Sale Price by Company (2021-2026) & (US$/kg)
Table 41. Key Manufacturers Antiviral Immunoglobulin Producing Area Distribution and Sales Area
Table 42. Players Antiviral Immunoglobulin Products Offered
Table 43. Antiviral Immunoglobulin Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Antiviral Immunoglobulin Sales by Geographic Region (2021-2026) & (kg)
Table 47. Global Antiviral Immunoglobulin Sales Market Share Geographic Region (2021-2026)
Table 48. Global Antiviral Immunoglobulin Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Antiviral Immunoglobulin Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Antiviral Immunoglobulin Sales by Country/Region (2021-2026) & (kg)
Table 51. Global Antiviral Immunoglobulin Sales Market Share by Country/Region (2021-2026)
Table 52. Global Antiviral Immunoglobulin Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Antiviral Immunoglobulin Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Antiviral Immunoglobulin Sales by Country (2021-2026) & (kg)
Table 55. Americas Antiviral Immunoglobulin Sales Market Share by Country (2021-2026)
Table 56. Americas Antiviral Immunoglobulin Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 58. Americas Antiviral Immunoglobulin Sales by Application (2021-2026) & (kg)
Table 59. APAC Antiviral Immunoglobulin Sales by Region (2021-2026) & (kg)
Table 60. APAC Antiviral Immunoglobulin Sales Market Share by Region (2021-2026)
Table 61. APAC Antiviral Immunoglobulin Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 63. APAC Antiviral Immunoglobulin Sales by Application (2021-2026) & (kg)
Table 64. Europe Antiviral Immunoglobulin Sales by Country (2021-2026) & (kg)
Table 65. Europe Antiviral Immunoglobulin Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 67. Europe Antiviral Immunoglobulin Sales by Application (2021-2026) & (kg)
Table 68. Middle East & Africa Antiviral Immunoglobulin Sales by Country (2021-2026) & (kg)
Table 69. Middle East & Africa Antiviral Immunoglobulin Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 71. Middle East & Africa Antiviral Immunoglobulin Sales by Application (2021-2026) & (kg)
Table 72. Key Market Drivers & Growth Opportunities of Antiviral Immunoglobulin
Table 73. Key Market Challenges & Risks of Antiviral Immunoglobulin
Table 74. Key Industry Trends of Antiviral Immunoglobulin
Table 75. Antiviral Immunoglobulin Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Antiviral Immunoglobulin Distributors List
Table 78. Antiviral Immunoglobulin Customer List
Table 79. Global Antiviral Immunoglobulin Sales Forecast by Region (2027-2032) & (kg)
Table 80. Global Antiviral Immunoglobulin Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Antiviral Immunoglobulin Sales Forecast by Country (2027-2032) & (kg)
Table 82. Americas Antiviral Immunoglobulin Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Antiviral Immunoglobulin Sales Forecast by Region (2027-2032) & (kg)
Table 84. APAC Antiviral Immunoglobulin Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Antiviral Immunoglobulin Sales Forecast by Country (2027-2032) & (kg)
Table 86. Europe Antiviral Immunoglobulin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Antiviral Immunoglobulin Sales Forecast by Country (2027-2032) & (kg)
Table 88. Middle East & Africa Antiviral Immunoglobulin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Antiviral Immunoglobulin Sales Forecast by Type (2027-2032) & (kg)
Table 90. Global Antiviral Immunoglobulin Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Antiviral Immunoglobulin Sales Forecast by Application (2027-2032) & (kg)
Table 92. Global Antiviral Immunoglobulin Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. ADMA Biologics (US) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 94. ADMA Biologics (US) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 95. ADMA Biologics (US) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 96. ADMA Biologics (US) Main Business
Table 97. ADMA Biologics (US) Latest Developments
Table 98. AstraZeneca (UK/Sweden) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 99. AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 100. AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 101. AstraZeneca (UK/Sweden) Main Business
Table 102. AstraZeneca (UK/Sweden) Latest Developments
Table 103. Bharat Serums & Vaccines (India) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 104. Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 105. Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 106. Bharat Serums & Vaccines (India) Main Business
Table 107. Bharat Serums & Vaccines (India) Latest Developments
Table 108. Biotest (Germany) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 109. Biotest (Germany) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 110. Biotest (Germany) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 111. Biotest (Germany) Main Business
Table 112. Biotest (Germany) Latest Developments
Table 113. Boya Bio (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 114. Boya Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 115. Boya Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 116. Boya Bio (China) Main Business
Table 117. Boya Bio (China) Latest Developments
Table 118. China Biologic Products (CNBG) (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 119. China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 120. China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 121. China Biologic Products (CNBG) (China) Main Business
Table 122. China Biologic Products (CNBG) (China) Latest Developments
Table 123. CSL Behring (US/Germany) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 124. CSL Behring (US/Germany) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 125. CSL Behring (US/Germany) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 126. CSL Behring (US/Germany) Main Business
Table 127. CSL Behring (US/Germany) Latest Developments
Table 128. Emergent BioSolutions (US) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 129. Emergent BioSolutions (US) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 130. Emergent BioSolutions (US) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 131. Emergent BioSolutions (US) Main Business
Table 132. Emergent BioSolutions (US) Latest Developments
Table 133. GC Pharma (S. Korea) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 134. GC Pharma (S. Korea) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 135. GC Pharma (S. Korea) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 136. GC Pharma (S. Korea) Main Business
Table 137. GC Pharma (S. Korea) Latest Developments
Table 138. Grifols (Spain) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 139. Grifols (Spain) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 140. Grifols (Spain) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 141. Grifols (Spain) Main Business
Table 142. Grifols (Spain) Latest Developments
Table 143. Hualan Biological (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 144. Hualan Biological (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 145. Hualan Biological (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 146. Hualan Biological (China) Main Business
Table 147. Hualan Biological (China) Latest Developments
Table 148. Intas Pharmaceuticals (India) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 149. Intas Pharmaceuticals (India) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 150. Intas Pharmaceuticals (India) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 151. Intas Pharmaceuticals (India) Main Business
Table 152. Intas Pharmaceuticals (India) Latest Developments
Table 153. Kamada (Israel) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 154. Kamada (Israel) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 155. Kamada (Israel) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 156. Kamada (Israel) Main Business
Table 157. Kamada (Israel) Latest Developments
Table 158. Kedrion (Italy) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 159. Kedrion (Italy) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 160. Kedrion (Italy) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 161. Kedrion (Italy) Main Business
Table 162. Kedrion (Italy) Latest Developments
Table 163. LFB Group (France) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 164. LFB Group (France) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 165. LFB Group (France) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 166. LFB Group (France) Main Business
Table 167. LFB Group (France) Latest Developments
Table 168. Octapharma (Switzerland) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 169. Octapharma (Switzerland) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 170. Octapharma (Switzerland) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 171. Octapharma (Switzerland) Main Business
Table 172. Octapharma (Switzerland) Latest Developments
Table 173. Regeneron (US) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 174. Regeneron (US) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 175. Regeneron (US) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 176. Regeneron (US) Main Business
Table 177. Regeneron (US) Latest Developments
Table 178. Roche (Switzerland) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 179. Roche (Switzerland) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 180. Roche (Switzerland) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 181. Roche (Switzerland) Main Business
Table 182. Roche (Switzerland) Latest Developments
Table 183. Sanofi (France) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 184. Sanofi (France) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 185. Sanofi (France) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 186. Sanofi (France) Main Business
Table 187. Sanofi (France) Latest Developments
Table 188. Shanghai RAAS (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 189. Shanghai RAAS (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 190. Shanghai RAAS (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 191. Shanghai RAAS (China) Main Business
Table 192. Shanghai RAAS (China) Latest Developments
Table 193. Shuanglin Bio (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 194. Shuanglin Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 195. Shuanglin Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 196. Shuanglin Bio (China) Main Business
Table 197. Shuanglin Bio (China) Latest Developments
Table 198. SK Plasma (S. Korea) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 199. SK Plasma (S. Korea) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 200. SK Plasma (S. Korea) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 201. SK Plasma (S. Korea) Main Business
Table 202. SK Plasma (S. Korea) Latest Developments
Table 203. Takeda Pharmaceutical (Japan) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 204. Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 205. Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 206. Takeda Pharmaceutical (Japan) Main Business
Table 207. Takeda Pharmaceutical (Japan) Latest Developments
Table 208. Tiantan Bio (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 209. Tiantan Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 210. Tiantan Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 211. Tiantan Bio (China) Main Business
Table 212. Tiantan Bio (China) Latest Developments
Table 213. Weiguang Biological (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 214. Weiguang Biological (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 215. Weiguang Biological (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 216. Weiguang Biological (China) Main Business
Table 217. Weiguang Biological (China) Latest Developments
Table 218. Yuanda Shuyang (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 219. Yuanda Shuyang (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 220. Yuanda Shuyang (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 221. Yuanda Shuyang (China) Main Business
Table 222. Yuanda Shuyang (China) Latest Developments
Table 1. Antiviral Immunoglobulin Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Antiviral Immunoglobulin Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Human Plasma Derived Polyclonal
Table 4. Major Players of Hyperimmune Specific Globulin
Table 5. Major Players of Recombinant Monoclonal Antibody (mAb)
Table 6. Major Players of Animal Derived (Equine/Ovine)
Table 7. Major Players of Others
Table 8. Global Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 9. Global Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Table 10. Global Antiviral Immunoglobulin Revenue by Type (2021-2026) & ($ million)
Table 11. Global Antiviral Immunoglobulin Revenue Market Share by Type (2021-2026)
Table 12. Global Antiviral Immunoglobulin Sale Price by Type (2021-2026) & (US$/kg)
Table 13. Major Players of Standard Fractionated Grade (90%?95%)
Table 14. Major Players of Clinical High Purity Grade (96%?98%)
Table 15. Major Players of Ultra Purified Specialty Grade(99%)
Table 16. Global Antiviral Immunoglobulin Sales by IgG Purity (2021-2026) & (kg)
Table 17. Global Antiviral Immunoglobulin Sales Market Share by IgG Purity (2021-2026)
Table 18. Global Antiviral Immunoglobulin Revenue by IgG Purity (2021-2026) & ($ million)
Table 19. Global Antiviral Immunoglobulin Revenue Market Share by IgG Purity (2021-2026)
Table 20. Global Antiviral Immunoglobulin Sale Price by IgG Purity (2021-2026) & (US$/kg)
Table 21. Major Players of Transplantation
Table 22. Major Players of Infectious Disease Prophylaxis
Table 23. Major Players of Immunodeficiency
Table 24. Major Players of Neurology (Autoimmune)
Table 25. Major Players of Others
Table 26. Global Antiviral Immunoglobulin Sales by Therapeutic Area (2021-2026) & (kg)
Table 27. Global Antiviral Immunoglobulin Sales Market Share by Therapeutic Area (2021-2026)
Table 28. Global Antiviral Immunoglobulin Revenue by Therapeutic Area (2021-2026) & ($ million)
Table 29. Global Antiviral Immunoglobulin Revenue Market Share by Therapeutic Area (2021-2026)
Table 30. Global Antiviral Immunoglobulin Sale Price by Therapeutic Area (2021-2026) & (US$/kg)
Table 31. Global Antiviral Immunoglobulin Sale by Application (2021-2026) & (kg)
Table 32. Global Antiviral Immunoglobulin Sale Market Share by Application (2021-2026)
Table 33. Global Antiviral Immunoglobulin Revenue by Application (2021-2026) & ($ million)
Table 34. Global Antiviral Immunoglobulin Revenue Market Share by Application (2021-2026)
Table 35. Global Antiviral Immunoglobulin Sale Price by Application (2021-2026) & (US$/kg)
Table 36. Global Antiviral Immunoglobulin Sales by Company (2021-2026) & (kg)
Table 37. Global Antiviral Immunoglobulin Sales Market Share by Company (2021-2026)
Table 38. Global Antiviral Immunoglobulin Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Antiviral Immunoglobulin Revenue Market Share by Company (2021-2026)
Table 40. Global Antiviral Immunoglobulin Sale Price by Company (2021-2026) & (US$/kg)
Table 41. Key Manufacturers Antiviral Immunoglobulin Producing Area Distribution and Sales Area
Table 42. Players Antiviral Immunoglobulin Products Offered
Table 43. Antiviral Immunoglobulin Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Antiviral Immunoglobulin Sales by Geographic Region (2021-2026) & (kg)
Table 47. Global Antiviral Immunoglobulin Sales Market Share Geographic Region (2021-2026)
Table 48. Global Antiviral Immunoglobulin Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Antiviral Immunoglobulin Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Antiviral Immunoglobulin Sales by Country/Region (2021-2026) & (kg)
Table 51. Global Antiviral Immunoglobulin Sales Market Share by Country/Region (2021-2026)
Table 52. Global Antiviral Immunoglobulin Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Antiviral Immunoglobulin Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Antiviral Immunoglobulin Sales by Country (2021-2026) & (kg)
Table 55. Americas Antiviral Immunoglobulin Sales Market Share by Country (2021-2026)
Table 56. Americas Antiviral Immunoglobulin Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 58. Americas Antiviral Immunoglobulin Sales by Application (2021-2026) & (kg)
Table 59. APAC Antiviral Immunoglobulin Sales by Region (2021-2026) & (kg)
Table 60. APAC Antiviral Immunoglobulin Sales Market Share by Region (2021-2026)
Table 61. APAC Antiviral Immunoglobulin Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 63. APAC Antiviral Immunoglobulin Sales by Application (2021-2026) & (kg)
Table 64. Europe Antiviral Immunoglobulin Sales by Country (2021-2026) & (kg)
Table 65. Europe Antiviral Immunoglobulin Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 67. Europe Antiviral Immunoglobulin Sales by Application (2021-2026) & (kg)
Table 68. Middle East & Africa Antiviral Immunoglobulin Sales by Country (2021-2026) & (kg)
Table 69. Middle East & Africa Antiviral Immunoglobulin Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Antiviral Immunoglobulin Sales by Type (2021-2026) & (kg)
Table 71. Middle East & Africa Antiviral Immunoglobulin Sales by Application (2021-2026) & (kg)
Table 72. Key Market Drivers & Growth Opportunities of Antiviral Immunoglobulin
Table 73. Key Market Challenges & Risks of Antiviral Immunoglobulin
Table 74. Key Industry Trends of Antiviral Immunoglobulin
Table 75. Antiviral Immunoglobulin Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Antiviral Immunoglobulin Distributors List
Table 78. Antiviral Immunoglobulin Customer List
Table 79. Global Antiviral Immunoglobulin Sales Forecast by Region (2027-2032) & (kg)
Table 80. Global Antiviral Immunoglobulin Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Antiviral Immunoglobulin Sales Forecast by Country (2027-2032) & (kg)
Table 82. Americas Antiviral Immunoglobulin Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Antiviral Immunoglobulin Sales Forecast by Region (2027-2032) & (kg)
Table 84. APAC Antiviral Immunoglobulin Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Antiviral Immunoglobulin Sales Forecast by Country (2027-2032) & (kg)
Table 86. Europe Antiviral Immunoglobulin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Antiviral Immunoglobulin Sales Forecast by Country (2027-2032) & (kg)
Table 88. Middle East & Africa Antiviral Immunoglobulin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Antiviral Immunoglobulin Sales Forecast by Type (2027-2032) & (kg)
Table 90. Global Antiviral Immunoglobulin Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Antiviral Immunoglobulin Sales Forecast by Application (2027-2032) & (kg)
Table 92. Global Antiviral Immunoglobulin Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. ADMA Biologics (US) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 94. ADMA Biologics (US) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 95. ADMA Biologics (US) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 96. ADMA Biologics (US) Main Business
Table 97. ADMA Biologics (US) Latest Developments
Table 98. AstraZeneca (UK/Sweden) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 99. AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 100. AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 101. AstraZeneca (UK/Sweden) Main Business
Table 102. AstraZeneca (UK/Sweden) Latest Developments
Table 103. Bharat Serums & Vaccines (India) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 104. Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 105. Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 106. Bharat Serums & Vaccines (India) Main Business
Table 107. Bharat Serums & Vaccines (India) Latest Developments
Table 108. Biotest (Germany) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 109. Biotest (Germany) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 110. Biotest (Germany) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 111. Biotest (Germany) Main Business
Table 112. Biotest (Germany) Latest Developments
Table 113. Boya Bio (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 114. Boya Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 115. Boya Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 116. Boya Bio (China) Main Business
Table 117. Boya Bio (China) Latest Developments
Table 118. China Biologic Products (CNBG) (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 119. China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 120. China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 121. China Biologic Products (CNBG) (China) Main Business
Table 122. China Biologic Products (CNBG) (China) Latest Developments
Table 123. CSL Behring (US/Germany) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 124. CSL Behring (US/Germany) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 125. CSL Behring (US/Germany) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 126. CSL Behring (US/Germany) Main Business
Table 127. CSL Behring (US/Germany) Latest Developments
Table 128. Emergent BioSolutions (US) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 129. Emergent BioSolutions (US) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 130. Emergent BioSolutions (US) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 131. Emergent BioSolutions (US) Main Business
Table 132. Emergent BioSolutions (US) Latest Developments
Table 133. GC Pharma (S. Korea) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 134. GC Pharma (S. Korea) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 135. GC Pharma (S. Korea) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 136. GC Pharma (S. Korea) Main Business
Table 137. GC Pharma (S. Korea) Latest Developments
Table 138. Grifols (Spain) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 139. Grifols (Spain) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 140. Grifols (Spain) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 141. Grifols (Spain) Main Business
Table 142. Grifols (Spain) Latest Developments
Table 143. Hualan Biological (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 144. Hualan Biological (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 145. Hualan Biological (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 146. Hualan Biological (China) Main Business
Table 147. Hualan Biological (China) Latest Developments
Table 148. Intas Pharmaceuticals (India) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 149. Intas Pharmaceuticals (India) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 150. Intas Pharmaceuticals (India) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 151. Intas Pharmaceuticals (India) Main Business
Table 152. Intas Pharmaceuticals (India) Latest Developments
Table 153. Kamada (Israel) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 154. Kamada (Israel) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 155. Kamada (Israel) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 156. Kamada (Israel) Main Business
Table 157. Kamada (Israel) Latest Developments
Table 158. Kedrion (Italy) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 159. Kedrion (Italy) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 160. Kedrion (Italy) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 161. Kedrion (Italy) Main Business
Table 162. Kedrion (Italy) Latest Developments
Table 163. LFB Group (France) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 164. LFB Group (France) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 165. LFB Group (France) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 166. LFB Group (France) Main Business
Table 167. LFB Group (France) Latest Developments
Table 168. Octapharma (Switzerland) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 169. Octapharma (Switzerland) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 170. Octapharma (Switzerland) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 171. Octapharma (Switzerland) Main Business
Table 172. Octapharma (Switzerland) Latest Developments
Table 173. Regeneron (US) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 174. Regeneron (US) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 175. Regeneron (US) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 176. Regeneron (US) Main Business
Table 177. Regeneron (US) Latest Developments
Table 178. Roche (Switzerland) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 179. Roche (Switzerland) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 180. Roche (Switzerland) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 181. Roche (Switzerland) Main Business
Table 182. Roche (Switzerland) Latest Developments
Table 183. Sanofi (France) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 184. Sanofi (France) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 185. Sanofi (France) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 186. Sanofi (France) Main Business
Table 187. Sanofi (France) Latest Developments
Table 188. Shanghai RAAS (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 189. Shanghai RAAS (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 190. Shanghai RAAS (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 191. Shanghai RAAS (China) Main Business
Table 192. Shanghai RAAS (China) Latest Developments
Table 193. Shuanglin Bio (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 194. Shuanglin Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 195. Shuanglin Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 196. Shuanglin Bio (China) Main Business
Table 197. Shuanglin Bio (China) Latest Developments
Table 198. SK Plasma (S. Korea) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 199. SK Plasma (S. Korea) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 200. SK Plasma (S. Korea) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 201. SK Plasma (S. Korea) Main Business
Table 202. SK Plasma (S. Korea) Latest Developments
Table 203. Takeda Pharmaceutical (Japan) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 204. Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 205. Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 206. Takeda Pharmaceutical (Japan) Main Business
Table 207. Takeda Pharmaceutical (Japan) Latest Developments
Table 208. Tiantan Bio (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 209. Tiantan Bio (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 210. Tiantan Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 211. Tiantan Bio (China) Main Business
Table 212. Tiantan Bio (China) Latest Developments
Table 213. Weiguang Biological (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 214. Weiguang Biological (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 215. Weiguang Biological (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 216. Weiguang Biological (China) Main Business
Table 217. Weiguang Biological (China) Latest Developments
Table 218. Yuanda Shuyang (China) Basic Information, Antiviral Immunoglobulin Manufacturing Base, Sales Area and Its Competitors
Table 219. Yuanda Shuyang (China) Antiviral Immunoglobulin Product Portfolios and Specifications
Table 220. Yuanda Shuyang (China) Antiviral Immunoglobulin Sales (kg), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 221. Yuanda Shuyang (China) Main Business
Table 222. Yuanda Shuyang (China) Latest Developments
LIST OF FIGURES
Figure 1. Picture of Antiviral Immunoglobulin
Figure 2. Antiviral Immunoglobulin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antiviral Immunoglobulin Sales Growth Rate 2021-2032 (kg)
Figure 7. Global Antiviral Immunoglobulin Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Antiviral Immunoglobulin Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Antiviral Immunoglobulin Sales Market Share by Country/Region (2025)
Figure 10. Antiviral Immunoglobulin Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Human Plasma Derived Polyclonal
Figure 12. Product Picture of Hyperimmune Specific Globulin
Figure 13. Product Picture of Recombinant Monoclonal Antibody (mAb)
Figure 14. Product Picture of Animal Derived (Equine/Ovine)
Figure 15. Product Picture of Others
Figure 16. Global Antiviral Immunoglobulin Sales Market Share by Type in 2026
Figure 17. Global Antiviral Immunoglobulin Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Standard Fractionated Grade (90%?95%)
Figure 19. Product Picture of Clinical High Purity Grade (96%?98%)
Figure 20. Product Picture of Ultra Purified Specialty Grade(99%)
Figure 21. Global Antiviral Immunoglobulin Sales Market Share by IgG Purity in 2026
Figure 22. Global Antiviral Immunoglobulin Revenue Market Share by IgG Purity (2021-2026)
Figure 23. Product Picture of Transplantation
Figure 24. Product Picture of Infectious Disease Prophylaxis
Figure 25. Product Picture of Immunodeficiency
Figure 26. Product Picture of Neurology (Autoimmune)
Figure 27. Product Picture of Others
Figure 28. Global Antiviral Immunoglobulin Sales Market Share by Therapeutic Area in 2026
Figure 29. Global Antiviral Immunoglobulin Revenue Market Share by Therapeutic Area (2021-2026)
Figure 30. Antiviral Immunoglobulin Consumed in Hospitals
Figure 31. Global Antiviral Immunoglobulin Market: Hospitals (2021-2026) & (kg)
Figure 32. Antiviral Immunoglobulin Consumed in Specialty Clinics
Figure 33. Global Antiviral Immunoglobulin Market: Specialty Clinics (2021-2026) & (kg)
Figure 34. Antiviral Immunoglobulin Consumed in Home Care
Figure 35. Global Antiviral Immunoglobulin Market: Home Care (2021-2026) & (kg)
Figure 36. Antiviral Immunoglobulin Consumed in Others
Figure 37. Global Antiviral Immunoglobulin Market: Others (2021-2026) & (kg)
Figure 38. Global Antiviral Immunoglobulin Sale Market Share by Application (2025)
Figure 39. Global Antiviral Immunoglobulin Revenue Market Share by Application in 2025
Figure 40. Antiviral Immunoglobulin Sales by Company in 2025 (kg)
Figure 41. Global Antiviral Immunoglobulin Sales Market Share by Company in 2025
Figure 42. Antiviral Immunoglobulin Revenue by Company in 2025 ($ millions)
Figure 43. Global Antiviral Immunoglobulin Revenue Market Share by Company in 2025
Figure 44. Global Antiviral Immunoglobulin Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global Antiviral Immunoglobulin Revenue Market Share by Geographic Region in 2025
Figure 46. Americas Antiviral Immunoglobulin Sales 2021-2026 (kg)
Figure 47. Americas Antiviral Immunoglobulin Revenue 2021-2026 ($ millions)
Figure 48. APAC Antiviral Immunoglobulin Sales 2021-2026 (kg)
Figure 49. APAC Antiviral Immunoglobulin Revenue 2021-2026 ($ millions)
Figure 50. Europe Antiviral Immunoglobulin Sales 2021-2026 (kg)
Figure 51. Europe Antiviral Immunoglobulin Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa Antiviral Immunoglobulin Sales 2021-2026 (kg)
Figure 53. Middle East & Africa Antiviral Immunoglobulin Revenue 2021-2026 ($ millions)
Figure 54. Americas Antiviral Immunoglobulin Sales Market Share by Country in 2025
Figure 55. Americas Antiviral Immunoglobulin Revenue Market Share by Country (2021-2026)
Figure 56. Americas Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Figure 57. Americas Antiviral Immunoglobulin Sales Market Share by Application (2021-2026)
Figure 58. United States Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC Antiviral Immunoglobulin Sales Market Share by Region in 2025
Figure 63. APAC Antiviral Immunoglobulin Revenue Market Share by Region (2021-2026)
Figure 64. APAC Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Figure 65. APAC Antiviral Immunoglobulin Sales Market Share by Application (2021-2026)
Figure 66. China Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 70. India Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe Antiviral Immunoglobulin Sales Market Share by Country in 2025
Figure 74. Europe Antiviral Immunoglobulin Revenue Market Share by Country (2021-2026)
Figure 75. Europe Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Figure 76. Europe Antiviral Immunoglobulin Sales Market Share by Application (2021-2026)
Figure 77. Germany Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 78. France Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 79. UK Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa Antiviral Immunoglobulin Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa Antiviral Immunoglobulin Sales Market Share by Application (2021-2026)
Figure 85. Egypt Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of Antiviral Immunoglobulin in 2026
Figure 91. Manufacturing Process Analysis of Antiviral Immunoglobulin
Figure 92. Industry Chain Structure of Antiviral Immunoglobulin
Figure 93. Channels of Distribution
Figure 94. Global Antiviral Immunoglobulin Sales Market Forecast by Region (2027-2032)
Figure 95. Global Antiviral Immunoglobulin Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global Antiviral Immunoglobulin Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global Antiviral Immunoglobulin Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global Antiviral Immunoglobulin Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global Antiviral Immunoglobulin Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Antiviral Immunoglobulin
Figure 2. Antiviral Immunoglobulin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antiviral Immunoglobulin Sales Growth Rate 2021-2032 (kg)
Figure 7. Global Antiviral Immunoglobulin Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Antiviral Immunoglobulin Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Antiviral Immunoglobulin Sales Market Share by Country/Region (2025)
Figure 10. Antiviral Immunoglobulin Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Human Plasma Derived Polyclonal
Figure 12. Product Picture of Hyperimmune Specific Globulin
Figure 13. Product Picture of Recombinant Monoclonal Antibody (mAb)
Figure 14. Product Picture of Animal Derived (Equine/Ovine)
Figure 15. Product Picture of Others
Figure 16. Global Antiviral Immunoglobulin Sales Market Share by Type in 2026
Figure 17. Global Antiviral Immunoglobulin Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Standard Fractionated Grade (90%?95%)
Figure 19. Product Picture of Clinical High Purity Grade (96%?98%)
Figure 20. Product Picture of Ultra Purified Specialty Grade(99%)
Figure 21. Global Antiviral Immunoglobulin Sales Market Share by IgG Purity in 2026
Figure 22. Global Antiviral Immunoglobulin Revenue Market Share by IgG Purity (2021-2026)
Figure 23. Product Picture of Transplantation
Figure 24. Product Picture of Infectious Disease Prophylaxis
Figure 25. Product Picture of Immunodeficiency
Figure 26. Product Picture of Neurology (Autoimmune)
Figure 27. Product Picture of Others
Figure 28. Global Antiviral Immunoglobulin Sales Market Share by Therapeutic Area in 2026
Figure 29. Global Antiviral Immunoglobulin Revenue Market Share by Therapeutic Area (2021-2026)
Figure 30. Antiviral Immunoglobulin Consumed in Hospitals
Figure 31. Global Antiviral Immunoglobulin Market: Hospitals (2021-2026) & (kg)
Figure 32. Antiviral Immunoglobulin Consumed in Specialty Clinics
Figure 33. Global Antiviral Immunoglobulin Market: Specialty Clinics (2021-2026) & (kg)
Figure 34. Antiviral Immunoglobulin Consumed in Home Care
Figure 35. Global Antiviral Immunoglobulin Market: Home Care (2021-2026) & (kg)
Figure 36. Antiviral Immunoglobulin Consumed in Others
Figure 37. Global Antiviral Immunoglobulin Market: Others (2021-2026) & (kg)
Figure 38. Global Antiviral Immunoglobulin Sale Market Share by Application (2025)
Figure 39. Global Antiviral Immunoglobulin Revenue Market Share by Application in 2025
Figure 40. Antiviral Immunoglobulin Sales by Company in 2025 (kg)
Figure 41. Global Antiviral Immunoglobulin Sales Market Share by Company in 2025
Figure 42. Antiviral Immunoglobulin Revenue by Company in 2025 ($ millions)
Figure 43. Global Antiviral Immunoglobulin Revenue Market Share by Company in 2025
Figure 44. Global Antiviral Immunoglobulin Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global Antiviral Immunoglobulin Revenue Market Share by Geographic Region in 2025
Figure 46. Americas Antiviral Immunoglobulin Sales 2021-2026 (kg)
Figure 47. Americas Antiviral Immunoglobulin Revenue 2021-2026 ($ millions)
Figure 48. APAC Antiviral Immunoglobulin Sales 2021-2026 (kg)
Figure 49. APAC Antiviral Immunoglobulin Revenue 2021-2026 ($ millions)
Figure 50. Europe Antiviral Immunoglobulin Sales 2021-2026 (kg)
Figure 51. Europe Antiviral Immunoglobulin Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa Antiviral Immunoglobulin Sales 2021-2026 (kg)
Figure 53. Middle East & Africa Antiviral Immunoglobulin Revenue 2021-2026 ($ millions)
Figure 54. Americas Antiviral Immunoglobulin Sales Market Share by Country in 2025
Figure 55. Americas Antiviral Immunoglobulin Revenue Market Share by Country (2021-2026)
Figure 56. Americas Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Figure 57. Americas Antiviral Immunoglobulin Sales Market Share by Application (2021-2026)
Figure 58. United States Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC Antiviral Immunoglobulin Sales Market Share by Region in 2025
Figure 63. APAC Antiviral Immunoglobulin Revenue Market Share by Region (2021-2026)
Figure 64. APAC Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Figure 65. APAC Antiviral Immunoglobulin Sales Market Share by Application (2021-2026)
Figure 66. China Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 70. India Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe Antiviral Immunoglobulin Sales Market Share by Country in 2025
Figure 74. Europe Antiviral Immunoglobulin Revenue Market Share by Country (2021-2026)
Figure 75. Europe Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Figure 76. Europe Antiviral Immunoglobulin Sales Market Share by Application (2021-2026)
Figure 77. Germany Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 78. France Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 79. UK Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa Antiviral Immunoglobulin Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa Antiviral Immunoglobulin Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa Antiviral Immunoglobulin Sales Market Share by Application (2021-2026)
Figure 85. Egypt Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries Antiviral Immunoglobulin Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of Antiviral Immunoglobulin in 2026
Figure 91. Manufacturing Process Analysis of Antiviral Immunoglobulin
Figure 92. Industry Chain Structure of Antiviral Immunoglobulin
Figure 93. Channels of Distribution
Figure 94. Global Antiviral Immunoglobulin Sales Market Forecast by Region (2027-2032)
Figure 95. Global Antiviral Immunoglobulin Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global Antiviral Immunoglobulin Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global Antiviral Immunoglobulin Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global Antiviral Immunoglobulin Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global Antiviral Immunoglobulin Revenue Market Share Forecast by Application (2027-2032)
